Evidence map›Paper›PMID 41364787›Full record

ArticleJMIR research protocols2025

The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.

Kristina Brenisin, Florence Kinnafick, James King, Louise Millard, Donna Arya, Elizabeth Hodgson, Michelle Huggins, Andrew Simmons-Roberts, Martin O'Dowd, Nick Rayment and 2 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kristina BrenisinSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0000-0003-3512-5535
Florence KinnafickNational Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.ORCID http://orcid.org/0000-0002-3095-7116
James KingNational Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.ORCID http://orcid.org/0000-0002-8174-9173
Louise MillardSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0000-0787-1763
Donna AryaSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0003-1839-3033
Elizabeth HodgsonSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0004-2935-7326
Michelle HugginsSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0000-0001-8293-9289
Andrew Simmons-RobertsSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0007-9789-2664
Martin O'DowdSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0005-8351-9362
Nick RaymentSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0001-5688-5405
Parul ShahSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0009-0007-5779-2271
Kieran C BreenSt Andrew's Healthcare, Billing Road, Northampton, NN1 5DG, United Kingdom, +44 1604 616049.ORCID http://orcid.org/0000-0003-3974-4237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antipsychotic-induced weight gain is a common side effect of antipsychotic drug treatment, particularly with second-generation medications such as clozapine and olanzapine. Weight gain in patients undergoing antipsychotic therapies is a significant concern, often compounded by factors related to their condition that can be particularly challenging in a secure care setting. While there is significant evidence to support the benefits of semaglutide, one of the available glucagon-like peptide-1 receptor agonists, in promoting weight loss for those who have a general weight-related health issue and meet the referral criteria for specialist services, it is unclear whether it will be as successful in people who have specifically gained weight due to medication-associated side effects and who reside in a secure care setting. Objective: This study aims to assess the impact of semaglutide in combination with a lifestyle behavior change intervention on the physical health measures of patients in a secure setting who have atypical antipsychotic-induced weight gain and identify enhancements to the intervention, specifically geared toward improving adherence and acceptability from both staff and patient perspectives. Methods: This 2-year uncontrolled pretest-posttest pilot study aims to recruit 20 inpatient participants. Adult patients of any diabetic status with a minimum BMI of 35.0 kg/m2 (or a BMI of 32.5 kg/m2 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean descent) who are receiving inpatient treatment and are treated with either olanzapine or clozapine will be eligible for inclusion in the study. Patients will receive semaglutide (Wegovy) at a maintenance dose of 2.4 mg once a week for 2 years. All participants will also receive a lifestyle behavior change intervention. Results: The findings will reveal whether the format of the interventional approach is both sustainable and effective for adult patients diagnosed with severe mental illness and living with obesity who are currently residing in a secure mental health setting. Implementation changes that could improve the acceptability of and adherence to the intervention will be explored. Conclusions: This research should be beneficial for patients with severe mental illness who are living with obesity and are residing in a secure setting as the findings may ultimately reduce the mortality risk in this patient group.

Indexed as

Antipsychotic AgentsGlucagon-Like PeptidesLife StyleAdultFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedOlanzapinePilot ProjectsSemaglutideWeight GainAntipsychotic AgentsGlucagon-Like Peptide 1Glucagon-Like PeptidesOlanzapineSemaglutideantipsychoticsbody weight lossdiabetesGLP-1glucagonlike peptide-1obesitysemaglutidesevere mental illness

Identifiers

PMID41364787
PMCPMC12688052

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.